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Abstract 
Objective 
Diagnostic test accuracy studies and meta-analyses may, in some cases, provide estimates 
which are highly improbable in practice; tailored meta-analysis provides a potential solution. 
To investigate the utility of tailored meta-analysis in synthesising estimates of a test’s 
accuracy compared with conventional meta-analysis for three case examples. 
 
Study design and setting 
MEDLINE, EMBASE, AND CINAHL were searched for relevant studies and routine data 
were collected on the test positive rate and disease prevalence from the case settings to define 
an applicable region for each setting. Three cases were evaluated: Mammography in the NHS 
Breast Screening Program; PHQ-9 questionnaire to screen for depression in general practice; 
Centor’s criteria used to diagnose group A beta-haemolytic streptococcus in general practice.  
For conventional meta-analysis, studies were selected using standard systematic review 
methods; for tailored meta-analysis this selection was refined to those with results compatible 
with the applicable region for the setting. 
 
Results 
In each example, studies were excluded as a result of incorporating an applicable region for 
the setting. Comparing tailored with conventional meta-analysis, the positive likelihood ratios 
(with 95% confidence intervals in brackets) were 36.5 (23.0-57.9) and 19.8 (12.8-30.9) 
respectively for mammography; and 4.89 (2.02-11.8) and 2.35 (1.51-3.67) respectively for 
Centor’s criteria. This had the effect of increasing the positive predictive value from 17 to 
27% for mammography and 23% to 38% for Centor’s criteria.  
 
Conclusion 
Tailored meta-analysis has the potential to provide a plausible estimate for a test’s accuracy 
which is specific to the practice setting. When compared with conventional meta-analysis, the 
difference may, in some cases, be sufficient to lead to different decisions on patient 
management. 
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What is new? 
This paper illustrates a novel method that provides a basis for evidence-based diagnosis in 
practice.  
 
Key findings 
The study demonstrates that routine data from real-life general practice and screening 
programmes may be combined with test evaluation research to assist in making decisions on 
the applicability of test research 
 
What was known? 
Meta-analysis may be used to synthesise summary estimates for a test’s sensitivity and 
specificity when there are multiple studies. However, these summary estimates may be 
unrepresentative of the test accuracy in practice, and may be virtually impossible to achieve 
in some cases. 
 
What this study adds 
Tailored meta-analysis may be used to synthesise estimates for a test’s accuracy that are 
customised to practice. Compared with estimates derived from conventional meta-analysis 
these may lead to different decisions on patient management. This method generalises to 
different tests and different settings including routine tests used in general practice. 
 
What is the implication 
The increased use of electronic patient records provides an opportunity to collect routine data 
on tests used in practice. If these are combined with test evaluation research there is the 
potential to improve diagnostic decision-making at an individual practice level.  
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Introduction 
One of the main concerns in diagnostic test research is the evaluation of a test’s accuracy. In 
relevant studies the objective is to determine how ‘accurate’ the test is at discriminating those 
patients with a target disorder from those who do not.  
 
Although, primary diagnostic test accuracy (DTA) studies do provide estimates of a test’s 
accuracy, these in general may vary between studies; being governed by factors relating to 
the conduct of the study, test execution and patient spectrum [1]. Some of the variation may 
be mitigated by standardizing the study conduct, but this is more difficult to achieve for the 
other factors. Hence a single study reports on the average performance for the test for 
circumstances particular to the study’s setting. This clearly has implications for meta-analysis 
and explains why heterogeneity is frequently observed [2]. 
 
In therapeutics, meta-analysis as a technique has been largely successful at ‘ironing out’ the 
effects of differences between individual studies to make assertions about the underlying 
effect [3]. In diagnostics such an approach may be taken to estimate the average performance 
of the test across all the studies [4,5]. However, for the specific question of ‘what is the 
performance of the test in my practice population’, it is not clear whether knowing the 
average accuracy across a number of studies is that useful, particularly when there is 
widespread heterogeneity. If a test’s performance in a particular practice is better represented 
by one of the outlier studies, the estimate derived from meta-analysis is likely to be 
significantly different from that experienced – indeed, in some cases the estimate may be 
virtually impossible in the practice setting of interest [6].  
 
It is this observation that motivated the development of a novel method which uses 
information from the target setting in order to select the studies most likely to be informative 
in practice [6]. Although the method has been developed and described in detail elsewhere its 
utility has yet to be fully investigated [6]. Here we will evaluate its utility in three case 
examples. In the first example, like the previous study [6], we will illustrate its use by 
applying it to a UK national screening programme. However, in the next two examples we 
will demonstrate for the first time how the method may help individual clinicians directly by 
applying it to a single general practice setting. 
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Method 
The aim is to provide a plausible estimate for the accuracy of a test within a specific setting 
without conducting a further primary study. Broadly, the approach relies upon using routine 
data from the target setting in order to define an ‘applicable region’ where the test’s 
performance is likely to lie [6]. This is used to ‘tailor’ the selection of included studies in a 
systematic review by excluding those that report test performances which are incompatible 
with this region [6]. 
 
The principal statistic for defining the applicable region is the test positive rate, r, which is 
obtained from counting the number of test positives in the setting at a particular threshold as a 
proportion of all those tested. Such data are collected routinely in the NHS screening 
programmes and it is increasingly possible to do the same in UK general practice through the 
electronics record systems. Having an estimate for r allows us to constrain the region in ROC 
space (after Receiver Operating Characteristic curve) where the sensitivity, s, and false 
positive rate, f, for the test must lie.  The size of the applicable region is dependent on both 
the size of r and its standard error. Thus, large sample sizes provide more precise, narrower 
applicable regions. 
 
The region may be refined further by including estimates of the prevalence, p, which if 
known without error will constrain the sensitivity and false positive rate to a straight line.
 
When the error in the estimate is incorporated the applicable region is narrowed usually to a 
trapezium-shaped area [6]. Thus, the applicable region for the setting represents the set of 
feasible values for the sensitivity and false positive rate given the estimates for the test 
positive rate and prevalence for the setting. This should be contrasted with the prediction 
region of conventional meta-analysis which is the model prediction on where a new study’s 
estimate would lie based only on data from the included studies [7]. The applicable region is 
in effect a prediction region, but more specific; it is for a particular setting based on data from 
the actual setting of interest. When there is no such data, the best prediction for the setting of 
interest would be provided by the prediction region otherwise it is provided by the applicable 
region. The corollary of this is where the prediction region lies outside of the applicable 
region this is an improbable estimate for the test in the setting. 
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Systematic review methods are used to provide an initial selection of studies for conventional 
meta-analysis. Each study’s compatibility with the setting is then determined by the 
magnitude of the tail probability of the study’s estimate for a potential study parameter lying 
in the applicable region. From all candidate parameters within the applicable region the 
maximum likelihood estimate is chosen when calculating probabilities - the level of 
significance is set to 0.025 for selecting studies. Consistent with previous analyses the 
sensitivity and false positive rate are assumed to have independent binomial distributions 
[5,6]. A summary of the process is given in appendix 1, and is detailed elsewhere [6].
 
 
Data collection 
Three diagnostic/screening tests were analysed using data collected from practice. In the first 
case, data were obtained from the NHS Breast screening programme (available in the public 
domain) and the applicable region was defined using r only. For the next two cases both r and 
p were used to define the applicable region for the test after collecting data from a single 
general practice in the UK. 
 
To obtain estimates on the accuracy of each of the tests analysed, the literature was searched 
for relevant meta-analyses. These provided the primary studies which were assessed for 
applicability in the target setting. Where appropriate, meta-analyses were either updated or 
synthesised de novo.  
 
Statistical methods used to aggregate studies 
The bivariate random effects model was used to derive summary estimates for the sensitivity 
and specificity (1 – false positive rate) [5] from which other relevant statistics were 
calculated. Confidence and predictions regions, as determined by methods previously 
described [8, 9] were also included in the figures. When the prediction region is much larger 
than the associated confidence region this suggests heterogeneity between studies [10]. The 
results of ‘tailored’ meta-analysis, where only applicable studies were aggregated were 
compared with ‘conventional’ meta-analysis where all the studies were aggregated. Unless 
otherwise stated, any estimate is followed by a 95% confidence interval (CI) in brackets. 
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 Results 
1. Breast Screening with mammography 
In the UK, there has been a national breast screening programme since 1988 [11]. It 
originally screened women between the ages 50-64 years with single view mammography, 
but since 2005 it has screened women between 50-70 years old with two-view mammography 
(mediolateral oblique and craniocaudal) triennially [11]. 
 
Following screening, patients are recalled for further investigation if, for technical reasons, 
the mammogram is an inadequate view or has features indicative of a potential abnormality 
[11]. Investigation involves further views, clinical or ultrasound examination or biopsy.  
 
Although several reviews have evaluated the efficacy of breast screening in terms of its effect 
on mortality [12-16] only one meta-analysis aimed to estimate the sensitivity and specificity 
of the mammogram as a screening test for breast cancer [17]. In that review they used the 
following definitions: a positive test result was when a patient was referred for further work-
up on the basis of the mammogram result; a false positive as those patients referred for 
further investigation and diagnosed negative by biopsy; and a false negative as a cancer 
detected in the interval between screens. 
 
The original meta-analysis published in 1998, included six studies in their analysis [17]. 
However, the studies reported on the first round (prevalent) screening performance and none 
reported on the programme screening performance which is mixture of prevalent and 
subsequent (or incident) screens.  In addition, as there have been several large-scale studies 
since this review, the analysis was updated (see appendix 2). Ten studies were included. 
 
In 2012, the NHS Breast Screening programme screened 1,722,677 women between the ages 
50-70 with a mammogram; 67,415 were referred for further assessment [18] – this equates to 
a test positive rate, r = 3.91% [99% CI: 3.88-3.95].  Imposing this on the results of the meta-
analysis leads to six of the ten included studies being outside the range of performance 
possible in the UK Breast Screening programme (figure 1). Only one study was conducted in 
the UK and it reported test performances which were compatible with the applicable region 
and was included. 
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For the conventional meta-analysis the sensitivity and specificity were 87.2% [95% CI: 81.1-
91.5] and 95.6% [95% CI: 93.0-97.3]. This compared to the tailored meta-analysis where the 
sensitivity and specificity were 78.0% [95% CI: 70.0-84.4] and 97.9% [95% CI: 96.4-98.7]. 
Although tailoring the study selection brings about a modest increase in specificity, the effect 
on the positive likelihood is more striking: 19.8 [95% CI: 12.8-30.9] compared with 36.5 
[95% CI: 23.0-57.9]. 
 
The NHS Breast screening programme reports 8.1 cases of breast cancer per 1000 women 
screened. This is likely to be an underestimate of the prevalence due to the presence of false 
negatives [18]. If we assume the background prevalence of breast cancer to be 1%, the effect 
of nearly doubling the positive likelihood ratio is to increase estimates of the post-test 
probability from 17% to 27%. Thus, when either the sensitivity or specificity is estimated to 
be close to 1, modest differences between estimates may have significant effects on the 
predictive values. 
 
2. Screening for depression using the PHQ-9 in general practice 
In general practice in the UK, the patient health questionnaire (PHQ-9) is most commonly 
used to monitor depression [19,20]. However, it was originally developed as a screening tool 
[21] and it is its accuracy as a screening tool that is of interest here. It consists of 9 questions 
with each question scored between 0 and 3, giving a maximum of 27 points. The usual 
threshold for a positive test result is 10 and all subsequent analyses will be at this threshold 
[21]. 
 
The accuracy of the PHQ-9 as a screening tool for depression was evaluated in a meta-
analysis published in 2012 [22]. Studies were included if the target disorder was a major 
depressive disorder as defined by a standardised diagnostic interview schedule based on the 
Diagnostic and Statistical manual of mental disorders (DSM) or the International 
Classification of Diseases (ICD).  
 
However, to estimate its performance in general practice and to capture the latest studies, a 
more specific meta-analysis was synthesised, where, in addition to the inclusion criteria 
above, we considered only those studies that had evaluated the tool in a family or general 
practice setting (see appendix 3).  
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There were ten included studies which reported the performance characteristics for the PHQ-
9 questionnaire at a test threshold of 10. Two studies evaluated an English version of the 
PHQ-9 questionnaire and only one study was located in the UK. There were also six different 
versions of the reference standard used between the studies which may have implications for 
the definition of the target disorder. 
 
To gain an insight on the performance of the PHQ-9 as a screening tool for depression in a 
particular general practice, audit data were collected on adult patients attending a general 
practice surgery of one of the authors (BHW) which has a patient population of circa 6500. 
In particular, those attending were asked to complete a PHQ-9 questionnaire, irrespective of 
their presenting complaint. Over a 6 week period, a total of 124 patients completed the 
questionnaire. Twenty-eight patients scored 10 or more, giving a test positive rate r = 22.6% 
[99% CI: 14.4-33.5]. Thus for the applicable region, r was taken to vary between 14.4 and 
33.5. 
 
To estimate the background prevalence of depression, a UK household survey of mental 
health carried out in 2007 was consulted [23]. These surveys are used to monitor the mental 
health of 16-74 year olds in the community. The methods involve interviewing subjects on 
average for 90 minutes, using the clinical interview schedule (CIS-R) to ascertain any mental 
health symptoms. These are then combined using a computer algorithm to give an ICD-10 
diagnosis. The survey reported a prevalence of depression of 2.8%, with 849 individuals 
taking part in the overall survey [23]. Based on this, a range of 1-10% was taken as the 
estimated prevalence range prior to testing.  
 
To summarise, the intervals 0.144 ≤  r ≤  0.335 and 0.01 ≤  p ≤  0.1 were used to derive the 
applicable region for the PHQ-9 tool in this general practice. Studies were then selected for 
tailored meta-analysis based on the individual study estimate being compatible (not 
improbable) with this region (see figure 2). 
 
Although the one UK-based study [24] was applicable to this general practice, the most 
striking feature is that three of the studies reported performances which were incompatible 
with this practice despite all being conducted in primary care settings. This adds weight to the 
argument that studies which are performed in settings that are prima facie similar to the 
practice setting may still be uninformative. 
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The effects on the performance characteristics were as follows: for conventional meta-
analysis the sensitivity and specificity were 74.2% [95% CI: 63.1-82.9] and 91.5% [95% CI: 
86.4.-94.8]; for tailored meta-analysis the sensitivity and specificity were 79.7 [95% CI: 71.5-
86.1] and 87.9 [95% CI: 83.1-91.5].  
 
In fact, the changes in all of the statistics were fairly modest and as a result would be unlikely 
to have any significant effect on clinical decision making. 
 
 
3. Using Centor’s criteria in the diagnosis of sore throats in general practice. 
Centor’s criteria is a clinical prediction rule used to diagnose group A beta haemolytic 
streptococcus (GABHS) infection in those patients presenting with a sore throat [25].  It 
consists of eliciting four clinical features from those patients presenting with a sore throat. 
The test result is usually considered positive when three or more features are found to be 
present [25]. 
 
Over the course of a 4-month period, 83 patients presented with a sore throat to the general 
practice of one of the authors (BHW) with a patient population of circa 6500. Each patient 
was tested using Centor’s criteria and the responses recorded. There were 7 [8.4%; 99% CI: 
3.4-19.6%] patients who scored 3 or more on Centor’s criteria. Thus, when imposing the 
constraints, r was taken to have a range of 0.34-0.196. 
 
To estimate the prevalence of GABHS in those attending with a sore throat, the first 45 
patients had their throats swabbed. The prevalence was found to be 11.1% [99% CI: 3.7%-
28.4%] and so p was considered to have the range of values 0.037-0.284 for the linear 
constraints.  
 
To estimate the accuracy of Centor’s criteria in general practice we reviewed the literature for 
studies which had evaluated the prediction rule in a primary care or general practice setting. 
The target disorder was GABHS and a throat swab was considered to be a suitable reference 
standard (see appendix 4 for details). In addition, the references from a previous meta-
analysis were located [26]. 
 11 
 
 
Twelve studies were included for analysis; none was in a UK setting. Although a sore throat 
was the predominant presenting symptom amongst patients selected, there was variation in 
the patient selection criteria between studies. Furthermore the age ranges of patients selected 
varied and blinding between the reference standard and test was not always reported. 
 
The results of applying constraints to the meta-analysis and defining an applicable region are 
given in figure 3. Five studies reported performances which were feasible in the practice 
setting analysed here. It is also worth reiterating that the seven excluded studies were all in 
primary care settings, supporting the hypothesis that superficial equivalence of setting does 
not necessarily lead to applicability. 
 
The corresponding sensitivity and specificity for the tailored meta-analysis were 38.4% [95% 
CI: 30.3-47.2] and 92.1% [95% CI: 83.4-96.5] respectively. In contrast the sensitivity and 
specificity estimated from the conventional meta-analysis were 50.3% [95% CI: 42.7-58.4] 
and 78.5% [95% CI: 65.7-87.5].  
 
The effects of using the different estimates of the likelihood ratios on the predictive values 
are considered in table 1. For a mean prevalence of GABHS of 11.1%, the more than 
doubling of the positive likelihood ratio may potentially lead to an increase in the PPV from 
23% to 38%. This could influence clinical decisions, such as whether to investigate further 
with other tests or to institute treatment without further testing.  
 
The performance statistics for all three tests are summarised in table 1. 
 
 
Discussion 
The central issue raised by the foregoing analysis is whether it is safe to apply the results of a 
DTA study or meta-analysis to clinical practice without more specific knowledge of the test 
in the intended setting than has hitherto been considered. 
 
One of the blights of meta-analysis in general is heterogeneity and it affects around 70% of 
meta-analyses of diagnostic test accuracy studies [2]. Indeed in each of the three cases 
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analysed here, the prediction regions were larger than the confidence regions for both tailored 
and conventional meta-analysis suggesting heterogeneity (figures 1-3). However, it should be 
noted that the size of the prediction region is also influenced by the number of studies and 
where there are few studies, such as in tailored meta-analysis, this significantly increases the 
region’s size irrespective of the tightness of clustering of the constituent studies. 
 
When there is heterogeneity, methodologists usually advocate hunting for the sources of 
variation by extending the base model with the relevant covariates [27]. In principle such a 
deterministic approach allows for biases to be studied and for homogeneous sub-groups to be 
defined. However, in practice, reviewers are often faced with insufficient data of adequate 
quality to initiate or at least be comprehensive with such analyses, as illustrated by the three 
examples evaluated here. As discussed earlier there are likely to be multiple factors 
contributing to the estimates reported by studies and meta-regression models may allow for 
the effects of study design factors such as blinding to be investigated. However, it is more 
difficult to incorporate in these models other important factors such as differences in patient 
spectrum, test execution and position of threshold.  
 
This has meant that clinicians and policy-makers have been left with a largely subjective 
decision on whether the results of a meta-analysis on a test’s accuracy are even plausible for 
their practice or not. Methods of appraisal of both primary studies individually and as part of 
a larger systematic review go some way to deciding when a study may be applicable. The 
limitations and problems arising from transferring results between different settings have also 
been described [1]. However, what seems to have been overlooked is the possibility of using 
more specific information on the clinical setting to help decide which studies are applicable 
particularly when the sources of heterogeneity between studies may be largely unknown. 
 
Specifically, estimates of the prevalence and the use of unverified test positive data from the 
practice setting can help determine which studies should be excluded from providing 
information on the test accuracy. Thus, the included studies report performances which lie 
within the range of possible performances for the test in that setting which is not always the 
case with conventional meta-analysis. The corollary of this is that without a tailored approach 
to study selection, conventional meta-analysis may provide summary estimates which are 
virtually impossible for the test in some settings – this was demonstrated when applying the 
results of a meta-analysis of the Pap test to the NHS Cervical screening programme [6]. As a 
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result, tailored meta-analysis provides a summary estimate that is at least plausible for the test 
in the setting.  
 
Of course plausibility does not necessarily equate to accuracy and without a separate primary 
study in the setting in question it is difficult to determine how close any estimate is to the 
‘true’ accuracy. Undoubtedly meta-regression [27] and, better still, individual patient data 
(IPD) analyses [28] would provide a more accurate estimate if the relative contributions that 
each of the factors which drive a test’s accuracy could be established.  The use of IPD has 
been at the forefront of recent prediction research and one proposed framework suggested 
that different model intercepts may be appropriate depending on the data available [29]. 
However, as with all model approaches, their effectiveness is contingent upon the availability 
of high quality data which ultimately depends on the adequate reporting of research. 
 
Thus, tailored meta-analysis represents a probabilistic and pragmatic approach to the question 
of applicability based on the information available. Consequently, any summary estimate 
should be interpreted as the most plausible estimate for the test in the setting in question 
given the available studies and the region of feasible performances for the test in the setting, 
(a comparison between conventional and tailored meta-analysis is given in table 2). 
 
Also of interest is the importance the test positive rate, r has in determining the size of the 
applicable region and hence the feasible values for the sensitivity and specificity [6]. Studies 
have shown how presenting symptoms may influence a test’s sensitivity and specificity [30] 
and a potential mechanism could be their effect on r. Once r is known, changing the 
prevalence also affects the shape of the applicable region. Thus, affirming empirical research 
that the sensitivity and specificity also depend on the prevalence [30,31]. 
 
Although defining an applicable region allows us to tailor the selection of studies for the test 
to the practice setting it is clear from the examples analysed that this does not always lead to 
a significant change in the aggregate estimates - such as in the case of applying the PHQ-9 
questionnaire to screen for depression. Nonetheless, there were two examples here where it 
was important, and, in a previous study, it was demonstrated to have a significant effect on 
the results [6]. This suggests that if information on the test positive rate, r and background 
prevalence, p, is available then it may be useful in meta-analysis. 
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As systems of data collection improve, knowing total numbers of test results is becoming 
increasingly possible at all levels from primary to tertiary care, as well as on a national scale. 
As a result, greater information on diagnostic and screening performance may influence 
policies on patient management and follow up. 
 
The example of applying Centor’s criteria to patients with sore throats, in general practice, 
establishes what may be achieved with a relatively small sample of test positive data from 
practice. A larger sample size would have narrowed the applicable region further and 
potentially refined the selection of studies more as a result. It also demonstrated that the 
methods extend beyond screening tests, even when the test positive rates are higher. Not only 
did the summary estimates from aggregating all studies lie outside the applicable region for 
the practice setting, the effect of using a more targeted selection of studies was to potentially 
increase the predictive value by 15%. 
 
It is clear, from the examples of the diagnostic/screening tests applied in general practice, that 
conducting studies in a similar setting (primary care) is not sufficient to guarantee that the 
findings will be applicable. This should be considered as a natural consequence of having 
more specific information on the target setting. It also suggests that external validity or 
generalizability of a study’s findings may be unachievable in some cases. 
 
Future research 
Although the benefits of taking a tailored approach to meta-analysis have been demonstrated, 
several areas relating to the method are worthy of further research. In particular, the current 
model has been developed within a classical framework but could be explored within a 
Bayesian framework. This would allow both the incorporating of prior information and the 
assessment of heterogeneity using a recently developed bivariate I
2
 statistic [32]. 
 
One of the shortcomings of tailored meta-analysis is a loss of statistical precision from 
excluding improbable studies. Whilst the potential for bias would not be eliminated, meta-
regression models that include some of the characteristics analysed here have the potential to 
improve the precision of summary estimates and could be investigated in future studies. 
 
In summary, the analysis given here demonstrates that performing meta-analyses without 
specific information regarding the intended clinical setting may result in misleading summary 
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statistics on a test’s performance. Furthermore, if information is available on the test positive 
rate and prevalence for the target setting, this should be used when deciding which studies are 
likely to provide a plausible estimate of performance within that setting. 
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Figure 1. Breast Screening using Mammography.  
Studies lying within the range of performance for the NHS Breast screening program (green 
rectangle) are depicted as red boxes. The corresponding summary performance estimate (red 
cross) and associated 95% confidence ellipse (red continuous) and prediction ellipse (red 
dashed) are also given. Studies outside the applicable region are depicted as blue triangles. 
For conventional meta-analysis (where all studies are included), the summary performance 
estimate (black cross) with 95% confidence ellipse (black continuous) and prediction ellipse 
(black dashed) are also given 
 
 
Figure 2. PHQ-9 as a screening tool for depression for a test threshold of 10.  
 
The applicable region for the general practice is represented by the green trapezium. The red 
coloured studies have performance estimates which lie in the applicable region for the 
practice and their associated summary estimate, confidence ellipse (continuous) and 
prediction ellipse (dashed) are also in red. Studies whose performances are improbable for the 
practice setting are depicted by the blue triangles. The overall summary estimate with 95% 
confidence ellipse (continuous) and prediction ellipse (dashed) from conventional meta-
analysis (where all studies were included) are in black. 
 
 
 
Figure 3. Centor’s criteria for diagnosing GABHS for a test threshold of 3. 
 
The applicable region for the general practice is represented by the green enclosed region. 
The applicable region is represented by the green trapezium. The red coloured studies have 
performance estimates which lie in the applicable region for the practice and their associated 
summary estimate, confidence ellipse and prediction ellipse (dashed) are also in red. Studies 
whose performances are improbable for the practice setting are depicted by the blue triangles. 
The overall summary estimate with 95% confidence ellipse and prediction ellipse from 
conventional meta-analysis (where all studies were included) are in black 
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Test Studies Sensitivity (%) Specificity (%) Positive LR Negative LR 
      
Mammography All (n=10) 87.2 (81.1-91.5) 95.6 (93.0-97.3) 19.8 (12.8-30.9) 0.13 (0.09-0.20) 
 AR (n=4) 78.0 (70.0-84.4) 97.9  (96.4-98.7) 36.5 (23.0-57.9) 0.22 (0.16-0.31) 
      
PHQ-9 All (n=10) 74.2 (63.1-82.9) 91.5 (86.4-94.8) 8.8 (5.7-13.5) 0.28 (0.20-0.41) 
 
AR (n=7) 79.7 (71.5-86.1) 87.9  (83.1-91.5) 6.6 (4.6-9.5) 0.23 (0.16-0.33) 
     
Centor All (n=12) 50.3 (42.7-58.4) 78.5 (65.7-87.5) 2.35 (1.51-3.67) 0.63 (0.54-0.73) 
 
AR (n=5) 38.4 (30.3-47.2) 92.1  (83.4-96.5) 4.89 (2.02-11.8) 0.67 (0.56-0.80) 
     
 
Table 1. Performance characteristics for the different tests as estimated by conventional 
meta-analysis and tailored meta-analysis. 
 
Note: LR = Likelihood ratio. All = all studies included in the analysis. AR = Applicable 
region – only those studies in the applicable region are in the analysis. 
95% confidence intervals in brackets. 
 
 
 
 
 
 
Conventional meta-analysis Tailored meta-analysis 
Criteria for study selection  Qualitative Qualitative and probabilistic 
Data from setting of interest Generally not used Yes, incorporates r and p from the 
setting when selecting studies 
Predicted location of test 
performance for setting of interest 
Prediction region Applicable region 
Applicability of summary estimate 
in setting of interest 
May be implausible for setting in 
some cases 
Plausible for setting 
Precision of summary estimate More precise Less precise. There may be too few 
studies to aggregate in some cases 
When should summary results be 
applied to practice 
When there is limited or no 
heterogeneity 
When there is heterogeneity and r 
and p are available for the setting 
 
Table 2. Comparison of conventional meta-analysis and tailored meta-analysis 
 
 
Appendix 1 Tailored meta-analysis model 
All studies that meet the inclusion criteria of the review are considered for selection for 
tailored meta-analysis by first deriving an applicable region for the test in the setting and 
comparing the observed estimate reported in each study with the applicable region. This is 
outlined below. 
 
a) Defining an applicable region based on the test positive rate, r 
Using data collected from the practice setting we may derive an interval estimate for the test 
positive rate r, such that we assume rlcl  μr   rucl where μr is the parameter for r, rlcl and rucl 
are the lower and upper confidence limits. This constrains the feasible values the sensitivity, s 
and false positive rate, f  may take in the practice setting, since  
 
if f   s then it follows that f   r and s ≥ r  (1) 
 
Combining this logical relation with the uncertainty of the interval estimate produces an 
applicable region (shaded) such as the one in illustration 1 below. 
 
   Illustration 1. 
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b) Defining an applicable region based on the test positive rate, r and prevalence, p 
Including information on the prevalence, p in addition to the test positive rate, r  allows us to 
refine the applicable region further by exploiting both (1) and the following relation  
 
 

s 
r
p

(1 p) f
p    (2) 
 
Using interval estimates we again assume that rlcl  μr   rucl and plcl  μp   pucl where μp is the 
parameter for p, plcl and pucl are the lower and upper confidence limits respectively. 
Combining (1) and (2) with the uncertainty of the interval estimates produces illustration 2. 
The two inner constraints (defined by [r = rucl ; p = pucl] and [r = rlcl ; p = plcl] respectively) 
are surplus since when the outer constraints are ‘violated’ so are the inner constraints, but the 
converse is not true.  
 
The effect these have on the size and shape of the applicable region (shaded) is shown in 
illustration 3. 
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c) Selecting studies based on their compatibility with the applicable region 
After deriving an applicable region for the test in the setting, for each primary study, we 
consider what the estimate for the false positive rate and sensitivity parameter pair (μf,i , μs,i) 
would be if it was constrained to lie in the applicable region.  
 
Consistent with the meta-analysis model of Chu and Cole [5] we assume the sensitivity and 
false positive rate for each study to have independent binomial distributions. We then derive 
the maximum likelihood estimate (MLE) for (μf,i , μs,i) subject to it being constrained to lie in 
the applicable region. This is made easier by noting that if the observed study estimate (fi , si) 
lies outside of the applicable region the MLE for (μf,i , μs,i) must lie on the closest boundary 
(see illustration 3).  
 
A tail probability for the observed study estimate (fi, si) may be calculated given the MLE of 
the parameter pair lying on the boundary and noting fi and si have independent binomial 
distributions as described above. A study i is excluded if the tail probability is less than the 
level of significance. The included studies are then aggregated using standard methods [5]. 
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Appendix 2: Update of meta-analysis of Mammography. 
The objective was to estimate the average sensitivity and specificity of mammography in the NHS 
breast screening programme in the UK by updating an earlier meta-analysis. 
 
Method  
Medline, EMBASE, and CINAHL were searched for studies published after 1996. Studies published 
prior to 1996 were retrieved from the results of a previous meta-analysis.
1
 Studies were included if: 
the study was a primary study; it evaluated two-view x-ray mammography as a screening test in a 
normal population cohort; a suitable reference standard was applied; a suitable threshold was applied; 
sufficient data were reported to complete the 2 x 2 table on the programme performance of 
mammography. 
 
The methodology relies upon the threshold between the data collected from practice and the primary 
studies being consistent. A suitable threshold for positive was a recommendation for further work-up‟ 
as in the UK or Breast Imaging Reporting and Data Systems (BIRADS) categories 0,3,4 and 5 as in 
the US.
2
 An acceptable reference standard was considered to involve biopsy confirmation of positives 
or linkage of patients to cancer registries. Negatives were confirmed by extended follow up such as 12 
months or more. From each included study the following data items were recorded: study identifier, 
the location of the study, details of the study population and when sampled, details of the technology 
and reference standard, number of readers, screening interval, definitions of positive and negative 
screens and 2 x 2 table data.  
 
The sensitivity and false positive rate (FPR) were estimated using conventional and tailored meta-
analysis. In the latter study selection is tailored to include only those that have estimates which are 
compatible with the NHS Breast screening programme (see main article). We intended to conduct 
meta-regression analyses but this was not possible due to insufficient studies in the sample. 
 
Results  
There were 862 citations (23 retrieved from previous meta-analysis for screening) and 10 studies were 
included for analysis. The set of included studies is given in Table A2a. Also shown in tables A2a and 
A2b are the study characteristics and the reported accuracies with inclusions decisions after each 
study has been compared with the applicable region for the NHS. The main risk of bias was in the 
reference standard due to the possibility of reviewer bias. None of the studies reported applying the 
reference standard blind to the index test, although, it was unclear due to inadequate reporting whether 
blinding featured in the study design. Six studies used a follow up period of 12 months for negative 
screens with the remaining studies following up over 24 months or more. There was also variation in 
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the length of follow up of negative screens with half. Although each study evaluated a screening 
population cohort the age range and the screening interval varied which could potentially introduce 
patient spectrum differences. The results of the conventional and tailored meta-analysis are given in 
the main article. 
 
Table A2a. Included studies 
A2.1.  
Muir TM, Tresham J, Fritschi L, Wylie E. Screening for breast cancer post reduction mammoplasty. 
Clin Radiol. 2010;65(3):198-205 
A2.2. 
Vernet Mdel M, Checa MA, Macià F, Casamitjana M, Carreras R.  Influence of hormone replacement 
therapy on the accuracy of screening mammography. Breast J.  2006; 12(2):154-8. 
A2.3a 
Hofvind S, Wang H, Thoresen S, Do the results of the process indicators in the Norwegian Breast 
Cancer Screening Program predict future mortality reduction from breast cancer? Acta 
Oncol. 2004;43(5):467-73. 
A2.3b 
Skaane P, Hofvind S, Skjennald A. Randomized trial of screen-film versus full-field digital 
mammography with soft-copy reading in population-based screening program: follow-up and final 
results of Oslo II study. Radiology. 2007;244(3):708-17 
A2.4 
Banks E, Reeves G, Beral V, Bull D, Crossley B, Simmonds M, Hilton E, et al. Influence of personal 
characteristics of individual women on sensitivity and specificity of mammography in the Million 
Women Study: cohort study. BMJ 2004;329(7464):477 
A2.5 
Elmore JG, Carney PA, Abraham LA, Barlow WE, Egger JR, Fosse JS, Cutter GR, Hendrick 
RE, D'Orsi CJ, Paliwal P, Taplin SH. The association between obesity and screening mammography 
accuracy. Arch Intern Med. 2004;164(10):1140-7. 
A2.6 
Bulliard JL, De Landtsheer JP, Levi F. Results from the Swiss mammography screening pilot 
programme. Eur J Cancer. 2003;39(12):1761-9 
A2.7 
Van Landeghem P, Bleyen L, De Backer G. Age-specific accuracy of initial versus subsequent 
mammography screening: results from the Ghent breast cancer-screening programme. European 
Journal of Cancer Prevention 2002;11:147–151 
A2.8a 
Rosenberg RD, Yankaskas BC, Hunt WC, Ballard-Barbash R, Urban N, Ernster VL et al. Effect of 
variations in operational definitions on performance estimates for screening mammography. Acad 
Radiol. 2000;7(12):1058-68 
A2.8b. 
Rosenberg RD, Lando JF, Hunt WC, Darling RR, Williamson MR, Linver MN et al.  Screening 
mammography performance in Albuquerque, New Mexico, 1991 to 1993. Cancer 1996; 78:1731-9. 
A2.9a 
Duijm LEM, Louwman MWJ, Groenewoud  JH, van de Poll-Franse LV, Fracheboud J, Coebergh JW. 
Inter-observer variability in mammography screening and effect of type and number of readers on 
screening outcome. British Journal of Cancer. 2009; 100: 901 – 907 
A2.9b 
Duijm LEM , Groenewoud  JH, Fracheboud J, de Koning HJ. Additional Double Reading of Screening 
Mammograms by Radiologic Technologists: Impact on Screening Performance Parameters. J Natl 
Cancer Inst 2007;99: 1162 – 70 
A2.10 
Seigneurin A, Exbrayat C, Labare` J, Colonna M. Comparison of interval breast cancer rates for two-
versus single-view screening mammography: A population-based study. Breast 2009;18: 284–288. 
 
Study id Population Study Design Readers Screening 
interval  
Follow up 
(months) 
A2.1 Women aged 49-69,  
Western Australia 
Retrospective cohort  
Jan 1998-Dec 2007 
2 2 years 12 
A2.2 Screening population 50-69,   
Barcelona, Spain 
Prospective cohort  
Jan 2000 - Dec 2002 
2 2 years 24 
A2.3a & 
A2.3b 
Women eligible for screening 45-49 and 
50-69. Oslo, Norway 
RCT on prospective cohort - 
Nov 2000-Dec 2001 
2 1 year for 45-49,  
2 years for 50-69. 
12 
A2.4 Women invited for screening, between 
50 -64, over 21 months. UK. 
Prospective cohort  
1996-1998 
Unclear 3 years 12 
A2.5 Women 40-79 eligible for screening. 
Group Health Cooperative NW US  
1996-2004 Unclear Unclear,  
probably 2 years 
12 
A2.6 Screening cohort 50-69, Lausanne, 
Switzerland 
Prospective cohort  
1993-1999 
2 2 years 27 
A2.7 All female residents 40-69 in city, 
screened over 8 years, Ghent, Belgium 
Prospective cohort  
1992-1999 
2 2 years 24 
A2.8a &  
A2.8b 
Female residents 35-84. Elected 
screening not invited.  Albuquerque, 
New Mexico 
Prospective cohort  
1991-1993 
1 1 year 12 
A2.9a & 
A2.9 b 
Women eligible for screening 50-75. 
Netherlands 
Retrospective cohort  
2003-2006 
1 and 2 2 years 24 
A2.10 Women eligible for screening 50-69.  
Isere, France 
Retrospective cohort  
1994-2004 
2 2.5 years til 2002, 
then 2 years. 
12 
 
Table A2b. Characteristics of the included studies. Readers = number of readers reading 
mammogram; follow up = time given before confirming a negative. 
 
Study id TP FN TN FP Sensitivity FPR p value Decision 
A2.1 3961 381 686719 32736 0.91 0.046 0 Exclude 
A2.2 92 12 22825 1331 0.88 0.055 0 Exclude 
A2.3a & b 2295 110 375150 15905 0.95 0.041 10-4 Exclude 
A2.4 629 97 117841 3885 0.87 0.032 1 Include 
A2.5 617 85 86272 13648 0.86 0.137 0 Exclude 
A2.6 68 28 9947 328 0.71 0.032 1 Include 
A2.7 195 52 28026 671 0.79 0.023 1 Include 
A2.8a & b 951 158 204870 25629 0.86 0.111 0 Exclude 
A2.9a & b 528 242 104403 920 0.69 0.009 1 Include 
A2.10 221 10 28881 2265 0.96 0.073 0 Exclude 
Table A2c.  Reported data and accuracy of included studies. „P value‟ shows the probability that the 
study estimate for the FPR and sensitivity could have arisen from the parameters („true values‟) lying 
in the applicable region for the NHS. The applicable region was defined based on 0.0388≤  r ≤ 0.0395 
(see main article); „Decision‟ is the decision to include/exclude for tailored meta-analysis for a level 
of significance of 0.025. 
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Appendix 3: Meta-analysis of the PHQ-9 questionnaire in General practice. 
The objective was to estimate the average sensitivity and specificity of the PHQ-9 questionnaire in 
diagnosing depression at a threshold of 10 in a general practice in the UK. 
 
Method  
Medline, EMBASE, and PsychInfo were searched for studies published after 1966 using a 
combination of search terms which included “phq” , “patient health questionnaire”, “depression”, 
“primary care”, “family practice”, “general practice”, “sensitivity”, “specificity”, “ROC curve” We 
also used citations from 3 existing meta-analyses. Studies were included if: the study was a primary 
study; it evaluated the PHQ-9 questionnaire in a general practice or family practice setting; the target 
diagnosis was a major depressive disorder; the reference standard was a standardised interview 
schedule based on the Diagnostic and Statistical manual of mental disorders (DSM IV) or the 
International Classification of Diseases (ICD-10); sufficient data were reported to complete the 2 x 2 
table at a test threshold of 10. 
 
The methodology relies upon the threshold between the data collected and the primary studies being 
consistent. In general when implementing the PHQ-9 tool the optimum threshold has been found to be 
10, so this was used when calculating the test positive rate from the routine data collected from the 
general practice setting. From each included study the following data items were recorded: study 
identifier; the location of the study; details of the study population; sampling; language of PHQ-9 
tool; reference standard; blinding between the test and reference standard; and 2 x 2 table data.  
 
The sensitivity and false positive rate (FPR) were estimated using conventional and tailored meta-
analysis using a bivariate random effects model (BRM) and the intention was to extend this model for 
meta-regression analyses to test for significant covariates if the sample of studies was adequate. 
  
Results  
The searches identified 139 unduplicated studies. After applying the inclusion criteria there were ten 
studies which evaluated the PHQ-9 on what may be considered an unselected adult primary care 
population (see table A3a). In seven studies the population was completely drawn from general or 
family practice and included all adults and both sexes. For the remaining three studies: one study 
selected 90% of the patients from general practice with the remainder drawn from hospital outpatients 
[A3.9]; the second study was conducted in hospital but this was the primary care entry point for the 
local population [A3.8]; the third selected only women from family practice but the selection was 
neither based on age nor co-morbidity [A3.10]. The characteristics of individual studies are shown in 
Table A3b. Meta-regression was not attempted owing to the small sample of studies (n = 10). 
A3.1.  
Arroll B, Goodyear-Smith F, Crengle S, Gunn J, Kerse N, Fishman T, Falloon K, Hatcher S. Validation of PHQ-2 and 
PHQ-9 to screen for major depression in the primary care population. Ann Fam Med. 2010;8:348-53 
A3.2. 
Ayalon L, Goldfracht M, Bech P. 'Do you think you suffer from depression?' Reevaluating the use of a single item 
question for the screening of depression in older primary care patients. Int J Geriatr Psychiatry. 2010;25(5):497-
502. 
A3.3 
Azah N. Shah M, Juwita S, Bahri I, Rushidi W, Jamil Y. Validation of the Malay version brief Patient Health 
Questionnaire (PHQ-9) among adult attending family medicine clinics. Int Med J 2005;12:259-64. 
A3.4 
Cheng C, Cheng M. To validate the Chinese version of the 2Q and PHQ-9 questionnaires in Hong Kong Chinese 
patients. HK Pract 2007;29:381-390 
A3.5 
Zuithoff NP, Vergouwe Y, King M, Nazareth I, van Wezep MJ, Moons KG, Geerlings MI. The Patient Health 
Questionnaire-9 for detection of major depressive disorder in primary care: consequences of current thresholds 
in a crosssectional study. BMC Fam Pract. 2010 ;11:98. 
A3.6 
Gilbody S, Richards D, Barkham M. Diagnosing depression in primary care using self-completed instruments: UK 
validation of PHQ–9 and CORE–OM BJGP 2007; 57: 650–652. 
A3.7 
Lotrakul M, Sumrithe S, Saipanish R. Reliability and validity of the Thai version of the PHQ-9. BMC Psychiatry. 
2008; 8:46. 
A3.8 
Inagaki M, Ohtsuki T, Yonemoto N, Kawashima Y, Saitoh A, Oikawa Y, Kurosawa M, Muramatsu K, Furukawa 
TA, Yamada M. Validity of the Patient Health Questionnaire (PHQ)-9 and PHQ-2 in general internal medicine 
primary care at a Japanese rural hospital: a cross-sectional study. Gen Hosp Psychiatry. 2013;35(6):592-7 
A3.9 
Liu SI, Yeh ZT, Huang HC, Sun FJ, Tjung JJ, Hwang LC, Shih YH, Yeh AW. Validation of Patient Health Questionnaire 
for depression screening among primary care patients in Taiwan. Compr Psychiatry. 2011 Jan-Feb;52(1):96-101 
A3.10. 
Sherina MS, Arroll B, Goodyear-Smith F. Criterion Validity of the PHQ-9 (Malay Version) in a Primary 
Care Clinic in Malaysia. Med J Malaysia. 2012;67(3):309-15 
 
Table A3a – The included studies 
 
 
Study id Population Location Sampling Language 
Reference 
standard 
Blinding 
A3.1 
Age > =16 in family practice in Auckland, 
New Zealand 
Auckland, New 
Zealand 
Consecutive English CIDI Yes 
A3.2 Family practice Israel Unclear ?Hebrew SCID-I Unclear 
A3.3 Adults in Family practice Kelantan, Malayasia Unclear Malay CIDI Yes 
A3.4 Adults in Family practice Hong Kong Consecutive Chinese HADS Yes 
A3.5 Age > =18 in family practice 
Utrecht, 
Netherlands 
Consecutive recruits Dutch CIDI Yes 
A3.6 General practice UK. Randomised English SCID-I Yes 
A3.7 GP clinic in Hospital Bangkok, Thailand Systematic sampling Thai 
MINI, 
HAM-D 
Yes 
A3.8 
 
Age > =19, outpatients in Hospital Tohoku, Japan 
Random sampling of 
consecutive patients 
Japanese MINI Yes 
A3.9 
Age > =18 in family practice & 10% in 
hospital outpatients 
Taipai, Taiwan Consecutive recruits Chinese SCAN Yes 
A3.10 Adult women in primary care Urban, Malaysia Consecutive Malayan CIDI  Yes 
 
Table A3b – Characteristics of studies.  
Note: CIDI – Composite International Diagnostic Interview; SCID – Structured Clinical Interview for DSM IV; HADS – 
Hospital Anxiety and Depression Scale; MINI – Mini-International Psychiatry Interview; HAM-D – Hamilton rating scale 
for Depression; SCAN – Schedule for Clinical Assessment in Neuropsychiatry. 
Although in each of the studies the reference standard took the form of a standardised interview, there 
were 6 different types used which could have implications for the definition of the target condition 
(Major depressive disorder). Blinding between the reference standard and the test was consistently 
reported across all but one of the studies. 
 
The PHQ-9 instrument was applied in English in only two studies and seven of the studies were 
conducted in the far-east. The sample size was too small to evaluate whether either of these factors 
could potentially affect the way the test is executed or have patient spectrum effects particularly when 
compared to a UK general practice setting.  
 
Imposing an applicable region for the practice as defined for  0.144 ≤  r ≤  0.335, 0.01 ≤  p ≤  0.1, (see 
main article) table A3c shows the 2 x 2 tables with the corresponding inclusions decisions after each 
study has been compared with the applicable region for the general practice setting. The results of the 
conventional and tailored meta-analysis are given in the main article 
 
Study id TP FN FP TN Sensitivity FPR p value Decision 
A3.1 121 42 220 2259 0.74 0.089 1 Include 
A3.2 4 2 2 145 0.67 0.014 0.000711 Exclude 
A3.3 18 12 29 121 0.60 0.193 1 Include 
A3.4 24 6 26 301 0.80 0.080 1 Include 
A3.5 86 89 59 1117 0.49 0.050 6.54 x 10-11 Exclude 
A3.6 33 3 13 47 0.92 0.217 1 Include 
A3.7 14 5 38 222 0.74 0.146 1 Include 
A3.8 4 3 2 95 0.57 0.021 0.00432 Exclude 
A3.9 43 7 90 1392 0.86 0.061 0.174508 Include 
A3.10 27 4 21 94 0.87 0.183 1 Include 
 
Table A3c. Reported data and accuracy of included studies. „P value‟ shows the probability that the 
study estimate for the FPR and sensitivity could have arisen from the parameters („true values‟) lying 
in the applicable region for the general practice setting; „Decision‟ is the decision to include/exclude 
for tailored meta-analysis for a level of significance of 0.025. 
 
 
 
 
  
Appendix 4: Meta-analysis of Centor’s criteria for diagnosing Group A β haemolytic 
streptococcus (GABHS) infection in general practice. 
The objective was to estimate the accuracy of Centors‟ criteria at a threshold of 3 in diagnosing 
GABHS infection in patients presenting with a sore throat in a general practice in the UK. 
 
Method  
Medline, EMBASE, and PsychInfo were searched for studies published after 1980 using a 
combination of search terms which included “streptococcal Infections”, “streptococc$”, “pharyngitis”, 
“sensitivity”, “specificity”, “ROC curve”, “predictive value of tests”. We also used citations from one 
published meta-analysis.
1
 Studies were included if: the study was a primary study; it evaluated 
Centor‟s criteria in an unselected general practice or family practice population; eligible subjects 
included those presenting with a sore throat; the target diagnosis was GABHS; the reference standard 
was by throat swab; sufficient data were reported to complete the 2 x 2 table at a test threshold of 3. 
 
The usual threshold when applying Centor‟s criteria to patients with a sore throat is 3 and this was 
used when calculating the test positive rate from data collected from the practice setting. For each 
included study the following data items were recorded: study identifier; the location of the study; 
details of the study population; sampling; reference standard; blinding between the test and reference 
standard; and 2 x 2 table data. The sensitivity and false positive rate (FPR) were using conventional 
and tailored meta-analysis and meta-regression analyses were planned if the sample of studies was 
adequate. 
  
Results  
We identified 506 unduplicated studies and eleven of these met the inclusion criteria (see table A4a). 
None of the studies was conducted in a UK setting. Although all studies selected subjects from a 
general practice population or equivalent, the age groups analysed in the individual studies varied. In 
four studies the study sample consisted of children only, in two studies the sampling was from an 
adult population and in the remaining studies the age range included both children and adults. 
 
There was also variation in the eligibility criteria for study subjects. In general patients were selected 
if they had symptoms of a sore throat, acute pharyngitis or an upper respiratory tract infection 
depending on the study. Such differences in entry criteria have the potential to affect the spectrum of 
patients tested. Studies which used one or more of Centor‟s criteria as part of the eligibility criteria 
were excluded. In six of the studies the mode of sampling was not clear and blinding between the test 
and the reference standard was in general inadequately reported. The study characteristics are shown 
in Table A4b and meta-regression was not performed owing to the small sample of studies (n = 11). 
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Table A4a – The included studies 
 
Table A4c shows the 2 x 2 tables with the corresponding inclusions decisions after each study has 
been compared with the applicable region for the general practice setting. Four of the eleven studies 
were included in the tailored meta-analysis. The results of the conventional and tailored meta-analysis 
are given in the main article 
 
 
  
Study 
id 
Population Location 
Selection criteria for study 
subjects 
Sampling Blinding 
A4.1 General population, age 3+  
500 clinics 
across US 
Painful throat & received 
GABHS testing 
Retrospective; 
unclear  
Unclear 
A4.2 Primary care, ages 2-14 
Asturias, 
Spain 
Acute pharyngitis, not 
defined 
Prospective; 
consecutive 
Yes 
A4.3 Primary care centre, age 14+ Madrid, Spain Sore throat 
Unclear; 
unclear 
Unclear 
A4.4 
Ambulatory care service of the 
social security program in OPD 
Hospital, age 15-65 
Bangkok, 
Thailand 
Symptoms of URTI: sore 
throat, rhinorrhoea 
Unclear; 
unclear 
Unclear 
A4.5 Primary care patients, age 18+ Boston, USA 
Symptoms of acute 
pharyngitis 
Prospective; 
consecutive  
Unclear 
A4.6 
Primary care patients, ages 4-
60 
Rotterdam, 
Netherlands 
Sore throat for < 15 days 
Prospective; 
unclear 
Unclear 
A4.7 Primary care setting,  age  2-17  
Wisconsin, 
USA 
All undergoing RADT for 
suspected GABHS 
Retrospective; 
consecutive 
Unclear 
A4.8 
Primary care patients in private 
health, ages 15-62 
Turku, Finland Sore throat 
Prospective; 
consecutive 
Unclear 
A4.9 
Family medicine patients, age 
3-14* 
Toronto, 
Canada 
Physician's opinion that they 
had an URTI 
Prospective; 
unclear 
Unclear 
A4.10 Family practice, age >7 Emek, Turkey 
Sore throat and no antibiotics 
in previous 3 days 
Prospective; 
unclear  
Unclear 
A4.11 
General practice in public 
hospitals and private clinics 
Makkah, 
Saudi Arabia 
Symptoms of pharyngo-
tonsillitis 
Prospective; 
unclear  
Unclear 
A4.12 Primary care, adults 
Michigan, 
USA 
Sore throat 
Prospective; 
consecutive 
Unclear 
 
Table A4b – Characteristics of studies.  
Note: The responses for sampling were related to design (prospective/retrospective/ unclear) and patient recruitment 
(consecutive/random/ systematic/unclear) respectively. 
* Although the study sample included patients with age range of 3-76, there was only sufficient data to complete 2 x 2 table 
for Centor‟s criteria in the age group 3-14. 
 
 
Study id TP FN FP TN Sensitivity FPR p value Decision 
A4.1 27299 28714 30218 120639 0.49 0.20 0 Exclude 
A4.2 40 34 73 45 0.54 0.62 0 Exclude 
A4.3 26 8 40 66 0.76 0.38 6.1 x 10-8 Exclude 
A4.4 7 16 9 260 0.30 0.03 1 Include 
A4.5 16 22 32 78 0.42 0.29 1.2 x 10-3 Exclude 
A4.6 116 67 131 244 0.63 0.35 4.5 x 10-16 Exclude 
A4.7 52 100 51 358 0.34 0.12 1 Include 
A4.8 4 1 17 84 0.80 0.17 1 Include 
A4.9 20 12 19 39 0.63 0.33 7.3 x 10-4 Exclude 
A4.10 13 19 38 212 0.41 0.15 1 Include 
A4.11 37 30 140 148 0.55 0.49 0 Exclude 
A4.12 6 2 1 71 0.75 0.01 1 Include 
 
Table A4c. Reported data and accuracy of included studies. „P value‟ shows the probability that the 
study estimate for the FPR and sensitivity could have arisen from the parameters („true values‟) lying 
in the applicable region for the general practice setting; „Decision‟ is the decision to include/exclude 
for tailored meta-analysis for a level of significance of 0.025. 
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